Press coverage about Regulus Therapeutics (NASDAQ:RGLS) has been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Regulus Therapeutics earned a daily sentiment score of 0.13 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 46.2014193863186 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Shares of Regulus Therapeutics traded down $0.02, reaching $0.69, during trading hours on Monday, according to Marketbeat. The company’s stock had a trading volume of 204,877 shares, compared to its average volume of 459,039. The company has a market capitalization of $74.07 million, a price-to-earnings ratio of -0.72 and a beta of 1.68. Regulus Therapeutics has a 1-year low of $0.61 and a 1-year high of $1.52.
Regulus Therapeutics (NASDAQ:RGLS) last issued its earnings results on Thursday, May 10th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.15). The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.02 million. Regulus Therapeutics had a negative return on equity of 214.48% and a negative net margin of 94,318.05%. equities analysts predict that Regulus Therapeutics will post -0.61 earnings per share for the current year.
RGLS has been the topic of several recent analyst reports. Zacks Investment Research downgraded Regulus Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, May 18th. B. Riley assumed coverage on Regulus Therapeutics in a report on Wednesday, March 28th. They issued a “neutral” rating and a $1.00 target price on the stock. Wedbush reiterated an “outperform” rating and issued a $3.00 target price on shares of Regulus Therapeutics in a report on Thursday, May 17th. ValuEngine upgraded Regulus Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, June 2nd. Finally, BMO Capital Markets set a $1.00 target price on Regulus Therapeutics and gave the company a “hold” rating in a report on Thursday, March 8th. Six research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $1.55.
About Regulus Therapeutics
Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.